Baricitinib

Baricitinib is a small molecule which can act as an Immunosuppressant; JAK1/2 inhibitor. It is provided as a white-to-off-white powder.

Baricitinib is an inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, baricitinib binds to JAK1/2, which inhibits JAK1/2 activation and leads to the inhibition of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This decreases the production of inflammatory cytokines and may prevent an inflammatory response. In addition, baricitinib may induce apoptosis and reduce proliferation of JAK1/2-expressing tumor cells. JAK kinases are intracellular enzymes involved in cytokine signaling, inflammation, immune function and hematopoiesis; they are also upregulated and/or mutated in various tumor cell types.

This product acts on the following target types: Kinase.
This product acts on the following biochemical pathways: Cytokine.
This product may be of interest in the following research areas and diseases: Immunology, Inflammation, Infectious disease.
This product may act as a Coronavirus inhibitor: Significantly improved COVID-19 symptoms in preliminary human trial, presumably through suppression of ""Cytokine storm"".

Please note that our chemical products are for scientific research use only and are not for medical or veterinary use. This product can only be dispatched to a scientific business or laboratory address.

Not applicable.

This product is for research use only.

Not for human consumption, cosmetic, therapeutic or diagnostic use.

Baricitinib